Market update Chordate Medical: “We have a favourable position” – Biostock interviews Anders Weilandt

In an interview with the news service Biostock, Chordate Medical’s CEO Anders Weilandt talks about ongoing market introductions around Europe, the market potential and the strategy going forward.

“During the many trips my colleagues and I have made recently to different countries and meetings in the field of migraines, I encounter everywhere a genuine interest from doctors in the clinical reality. I see in the response how significant our treatment method potentially could be on a global level”, says Anders Weilandt in the interview.

The full interview can be found here.

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy